XML 47 R22.htm IDEA: XBRL DOCUMENT v3.10.0.1
Geographic Segments
 12 Months Ended
Jun. 30, 2018
Segment Reporting [Abstract]  
Geographic Segments
Geographic Segments
Immunomedics manages its operations as one line of business of researching, developing, manufacturing and marketing biopharmaceutical products, particularly antibody-based products for cancer and other serious diseases, and it currently reports as a single industry segment. Immunomedics conducts its research and development activities primarily in the United States Immunomedics marketed and sold LeukoScan® throughout Europe and in certain other countries outside the United States The Company discontinued the sale of LeukoScan® during the third quarter of 2018 to focus on its ADC business.

The following table presents financial information based on the geographic location of the facilities of Immunomedics as of and for the years ended (in thousands):
 
June 30,
 
2018
 
2017
Total assets:

 


United States
$
662,519

 
$
161,484

Europe
1,654

 
1,089

   Total
$
664,173

 
$
162,573


 
June 30,
 
2018
 
2017
Property and equipment, net:


 


United States
$
15,649

 
$
5,166

Europe
84

 
79

   Total
$
15,733

 
$
5,245

 
 
June 30,
 
2018
 
2017
 
2016
Revenues:


 


 


United States
$
655

 
$
648

 
$
972

Europe
1,501

 
2,443

 
2,261

   Total
2,156

 
3,091

 
3,233

 
 
 
 
 
 
(Loss) income before taxes:
 
 
 
 
 
United States
(274,260
)
 
(153,348
)
 
(63,688
)
Europe
529

 
103

 
(502
)
   Total
$
(273,731
)
 
$
(153,245
)
 
$
(64,190
)